Summary We studied the mouse NC tumour, a subcutaneously transplanted adenocarcinoma originally of mammary origin. Measurements per g tissue were made of 17 fatty acids (FAs), the combined amounts of n-3, n-6, saturated, unsaturated, and total FAs, and of various FA ratios in the tumour, mammary tissue, spleen, liver and plasma. Compared with mammary tissue from normal mice, tumours of vehicle-treated controls had less of seven of the FAs and more of two FAs. Mice bearing the NC tumour often had changed (usually decreased) amounts of FAs in the 'normal' spleen, liver and plasma, but not in mammary tissue. Treatment with methotrexate (MTX) was studied alone and with indomethacin which can potentiate MTX cytotoxicity. Indomethacin 1.25 mg kg-' (INDO) increased the amounts of 3/17 tumour FAs and the unsaturated FAs, but reduced 9/17 FAs, the saturated and the unsaturated FAs in 'normal' mammary tissue, and usually had no effect on the FAs of other tissues. MTX 2 or 4 mg kg-' (MTX 2 or 4 mg) ± INDO in general partly restored (increased) the amounts of tumour FAs, and reduced the saturated/unsaturated FA ratio. In the 'normal' spleen and plasma also, but not in the liver, MTX 2 mg generally somewhat restored the FA composition. However, as in the liver, the spleen 20:4 and 22:6 (which form prostaglandins and lipid peroxides) did not increase in the presence of INDO. With MTX 4 mg, some of the plasma and liver FAs decreased, in contrast to the tumour. There was generally no evidence of MTX potentiation by INDO. These results are discussed in relation to carcinogenesis, cachexia, and the response to treatment.
Relationships between lipids and cancer are not fully understood. Some epidemiological studies suggest the involvement of dietary fats in human cancer development (Correa, 1981; Holm et al., 1989; Prentice et al., 1989; Young & Young, 1989) ; both the quality and quantity of dietary fats might influence tumour incidence. In animal studies, linoleic acid (an n-6 FA) promoted tumour growth and development, with concomitant increases of eicosanoid synthesis and cell division, and depression of the immune response (Karmali, 1987) . Conversely, diets rich in n-3 FAs inhibited some cancers, possibly by decreasing arachidonate metabolism (Karmali, 1987; Abou-EI-Ela et al., 1988) .
Cancer cachexia, the weight loss that can accompany malignancy, involves gross metabolic disturbance. In mice, this was reduced by dietary manipulation with fish oil (Tisdale & Dhesi, 1990) or by treatment with indomethacin (Gelin et al., 1991) . FA changes seen in our experiments might be relevant to this condition.
Our research into methotrexate (MTX) started because we found that the cyclo-oxygenase inhibitors flurbiprofen and indomethacin (INDO) decreased cancer development and spread (Bennett et al., 1979 . We then demonstrated that INDO potentiates the anticancer effect of MTX in vitro and in vivo. The mechanism is not clear, but the effect in vitro probably does not involve MTX displacement from binding sites on serum proteins, or inhibition of prostaglandin formation, cAMP phosphodiesterase or of calcium transport (Gaffen et al., 1985 (Gaffen et al., , 1989 Bennett et al., 1987; Gaffen et al., 1991) . Possibilities examined in the present study are whether INDO and MTX alone and together affect the fatty acids (FAs) of malignant and 'normal' tissues, and whether the potentiation of MTX cytotoxicity involves alteration of tumour FA composition. We have therefore measured various FAs in extracts of mouse NC tumour, mammary tissue, spleen, liver and plasma, and the effects of MTX and INDO on them.
Ratios of 16:0/16:1, 18:0/18:1, 18:2/20:4, 20:3/20:4, n-6/ n-3 and saturated/unsaturated fatty acids have been examined for various reasons. The degree of saturation affects membrane fluidity and permeability (Schlager & Ohanian, 1980a) ; 18:0/18:1 is lower in red cell membranes from cancer patients (Wood et al., 1985) ; the latter ratio and 16:0/16:1 indicate delta-9-desaturase activity; the 18:2/20:4 ratio reflects delta-6-denaturase, elongase and delta-5-desaturase activities and eicosanoid production (Fulton, 1984; Hubbard et al., 1988) ; 20:3/20:4 reflects delta-5-desaturase activity; the n-6/n-3 ratio indicates tumour aggressiveness which is high when n-6 levels are low (Lanson et al., 1990 ).
Materials and methods
Mouse treatment in vivo The NC carcinoma used in these studies arose initially in the mammary region of a WHT/Ht mouse (Hewitt et al., 1976) and has been transplanted in the same strain since then. Metastasis to the lungs and mediastinum, local lymphatic spread and recurrence in the excision scar commonly occur.
Female WHT/Ht mice aged 2-4 months and weighing 24-27 g at the start of the experiment were fed SDS No. 1 modified diet (Special Diet Services Ltd., Essex, UK) and had free access to water. They were weighed at intervals of 2-4 days starting 10 days before tumour transplantation; during this short experiment there were no significant differences between the groups. The two separate experiments resulted in combined numbers of six to nine mice in each of the seven groups. On day 0 all but one group of mice were injected s.c. into the left flank with approximately 106 NC carcinoma cells (Bennett et al., 1979 44 and 57% respectively, whereas INDO alone or with MTX 2 mg had little or no effect (Table   I) .
At day 18 the spleens from normal mice given vehicle weighed 72 mg (30-110), whereas those from mice with untreated tumours were 85% heavier (P <0.003). Treatment with MTX 4 mg + INDO decreased the spleen weight to 109 and 85 mg (51 and 18% respectively more than in normal mice). MTX 2 mg ± INDO tended to reduce the spleen weight, but INDO alone had no effect ( Table I) .
The weight of livers from normal mice was 1.21 g (1.11-1.32), about the same as in the cancer-bearing groups, and was unchanged by drug treatment.
Fatty acid changes
Since there are seven groups each with measurements of 17 FAs, combined amounts of n-3, n-6, saturated, unsaturated and total FAs, and calculations of various ratios, it is to be expected that by chance some analyses will indicate a statistically significant difference when none really exists (a Type I error). Nevertheless, it seems that at least some of the treatments resulted in genuine changes. Because of the large amount of data, we have selected for discussion the aspects mainly related to tumour FAs, the effects of the tumour on normal tissue FAs, and to a possible MTX/INDO interaction. Details of all aspects are presented in the Tables.
The FAs in 'normal' tissues from tumour-bearing vehicletreated mice are compared with normal controls (i.e. no cancer) that received only vehicle. FAs in the drug-treated groups are compared with tissues from vehicle-treated tumour-bearing mice.
Tumour fatty acids FAs (18:2, 20:2, 20:3, 20:4, 22 :2 and 22:4) increased with MTX 2 mg ± INDO or MTX 4 mg alone. The n-6/n-3 ratio also increased, because the combined amounts of the n-3 FAs (18:3, 18:4, 20:5 and 22:6) were not significantly changed.
In the MTX 4 mg ± INDO groups the ratio of tumour 18:2/20:4 was generally greater, while 18:0/18:1 was less, compared with control tumours.
Mammary fatty acids
These results are shown in Table III 18:3, 20:1, 20:3, 20:4 and 22:4) , but there was more 20:5. The cancer group had higher ratios of spleen 16:0/16:1, 18:0/18:1, saturated/unsaturated FAs, but lower ratios of 18:2/20:4 and n-6/n-3. Drug effects MTX 2 mg + INDO increased 6/9 of the tumour-depressed spleen FAs towards normal (14:0, 16:1, 18:1, 18:2, 18:3, 20:1) and tended to 'normalise' the combined amounts of unsaturated FAs, total FAs, 16:0/16:1, 18:0/18: 1, n-6/n-3, and saturated/unsaturated FAs). MTX 2 mg alone tended to 'normalise' three depressed FAs (20:3, 20:4, 22:4) , n-6 unsaturated FAs, and the total FAs. Compared to MTX 2 mg + INDO there were fewer changes with MTX 4 mg + INDO, and some of these were in the opposite direction. INDO alone had no significant effect, but tended to inhibit the effect of MTX 2 mg on n-3, n-6, 20:3, 20:4, 22:4 and 22:6 FAs.
Discussion
Modification of cellular FA composition may affect physical properties such as membrane fluidity and permeability, and certain cellular functions including transport systems, receptor binding, and eicosanoid production (De Kruyff et al., 1973; King et al., 1977; King & Spector, 1978) . These might change the responses of cells to hormones, and their susceptibility to immune attack (Burns et al., 1979; Fulton & Heppner, 1985; Guffy et al., 1984; Schlager & Ohanian, 1979 , 1980a .
Fatty acid changes in malignancy Wood et al. (1985) found increased desaturation of stearic (18:0) to oleic acid (18:1) in red cell membranes from patients with colorectal cancer, and a consequently decreased 18:0/18:1 ratio. We found a similar change in the plasma 18:0/18:1 ratio in the tumour-bearing mice, but the reverse in the liver and spleen. Tumour-bearing mice usually had less of some FAs in the spleen, liver and plasma, but there was little 495.0 (378-554) 7.6 (7.1-10.5) 10.4 (7.4-14.6) 5.6 (2.3-5.7) 6.0 (4.5-7.5) 19.4 (11.0-20.8) 23.0 (21.5-24.5) 426.0 (281-435) 62.0 (61.0-85.4) 52.9 (31.9-60.8) 5.8 (4.8-6.9) 120.0 (99.1-137) 203.0 (198-250) (Burns et al., 1979; Burns & North, 1986) , and effective cytotoxic drugs caused an overall rise in the unsaturated FA content of cells (Schlager et al., 1980b) . In our experiments MTX increased the tumour content of unsaturated FAs, and this effect might alter the cell membrane permeability and thickness (Schlager & Ohanian, 1980a,b) .
Methotrexate/indomethacin interaction The MTX/INDO interaction is important because INDO potentiates both the MTX-induced prolongation of survival of mice with NC tumours, and the killing of NC cells and human breast cancer cells in culture (Bennett et al., 1987) . The mechanism(s) are not fully understood, but we recently found that INDO potentiated the changes in FA composition induced by MTX in cultured NC cells (Soydan et al., 1991) . However, potentiation rarely occurred in the present in vivo experiments.
Our previous results in vitro indicate that the effect does not involve MTX displacement from binding sites on serum proteins, or inhibition of prostaglandin formation, cAMP phosphodiesterase or of calcium transport (Gaffen et al., 1985 (Gaffen et al., , 1989 Bennett et al., 1987; Gaffen et al., 1991) . However, inhibition of prostaglandin synthesis seems to explain the prolongation of survival by INDO in NC tumour-bearing mice , and we have not excluded the possibility that this mechanisms may contribute to the potentiation of MTX cytotoxicity in vivo. The spleen can synthesise large amounts of prostanoids such as PGE2, PGI2 and thromboxane A2 (Pace-Asciak & Rangaraj, 1977; Hidaka et al., 1983) , and these prostanoids might affect the host response to the tumour (Bennett, 1982) . In the NC tumour and spleen, amounts of 20:4 (the precursor of the 2-series prostaglandins) increased somewhat with MTX 2 mg. Perhaps the potentiation of MTX cytotoxicity by INDO in vivo (Bennett et al., 1987) involves a decrease in the formation of immunosuppressive PGE2, particularly since MTX itself causes immunosuppression (Jackson, 1984; Chabner et al., 1985) , and cytotoxic drugs can increase prostaglandin release (Levine, 1977; Berstock et al., 1980) . Prostaglandins are not the only lipids that can influence the immune system, and linoleate alone or in metabolic relationships with arachidonate and prostaglandins might be involved (Plescia et al., 1975) . Mammary tumour cells synthesise primarily 18:3, 20:3 and 20:4 FAs from 18:2 (Chapkin et al., 1989) , indicating the presence of desaturase and elongase enzymes. In our cancer-bearing mice, MTX 4 mg + INDO decreased the 18:2/20:4 ratio in the spleen, but increased it in the tumour. These results might reflect changed enzymic activities and/or prostaglandin production (Fulton, 1984; Hubbard et al., 1988 The amounts of FAs (ug g-, given to three significant figures) are shown as median values with interquartile ranges in parentheses. The treatment groups (n = 6, including the normal mice without tumour) are expressed as percentages of the vehicle-treated tumour-bearing controls (n = 9). P values <0.1, b<0.05, C<0.02, d< 0.002. 20:2 was not detected (ND) in any of the groups examined. Fatty acid ratios are shown at the bottom of the table. 
